Journal
AUTOIMMUNITY REVIEWS
Volume 20, Issue 2, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.autrev.2020.102731
Keywords
Autoimmunity; Immune mediated inflammatory disease; Spondyloarthritis; Psoriatic arthritis; Spondylitis; Psoriasis; Enthesitis; Enterocolitis; Dactylitis; Uveitis; Peripheral synovitis; Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Noninfectious uveitis
Categories
Funding
- Independent Research Fund Denmark [9039-00015B]
- Danish Ministry of Health
Ask authors/readers for more resources
This article discusses the distinct group of axial spondyloarthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and noninfectious uveitis, and reviews new targeted pharmacological treatment options for these diseases. It highlights the efficacy of different drugs, such as TNF inhibitors and specific inhibitors for certain inflamed tissues, and aims to assist clinicians in making stratified treatment decisions for patients with this disease spectrum.
Axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), psoriasis, inflammatory bowel disease (IBD), and noninfectious uveitis form a distinct group among the immune mediated inflammatory diseases. Thus, many patients suffer from more than one of these disease manifestations. Here, we will use the term spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) spectrum disease. The aim is to review the new targeted pharmacological treatment options for all these diseases. All biological or targeted synthetic drugs with U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval for any of the diagnoses axSpA, PsA, psoriasis, IBD, or non-infectious uveitis were included. Some of the drugs have documented efficacy in more than one of the diseases, e.g. tumor necrosis factor (TNF) inhibitors. However, other drugs are particularly effective for a specific inflamed tissue and approved in only one or two of the disease entities, e.g. abatacept for peripheral arthritis and vedolizumab for inflammatory bowel disease. This contributes with bedside to bench understanding of the immunology underlying this disease spectrum and provides clinicians with an overview that can assist stratified treatment decisions. We hope that this review will help guide clinicians to speed up treatment of patients with this disease spectrum.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available